Sergei I. Petrykiv
Groningen, GR, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Exposure-response relationships for the sodium-glucose co-transporter-2 inhibitor dapagliflozin with regard to renal risk markers.
Journal: Diabetes, obesity & metabolism
Published: November 27, 2019
Effects of Dapagliflozin on Circulating Markers of Phosphate Homeostasis.
Journal: Clinical journal of the American Society of Nephrology : CJASN
Published: April 11, 2018
Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers.
Journal: Diabetes, obesity & metabolism
Published: January 21, 2018
Does SGLT2 inhibition with dapagliflozin overcome individual therapy resistance to RAAS inhibition?
Journal: Diabetes, obesity & metabolism
Published: May 31, 2017
The albuminuria-lowering response to dapagliflozin is variable and reproducible among individual patients.
Journal: Diabetes, obesity & metabolism
Published: February 05, 2017
Pooled Analysis of Multiple Crossover Trials To Optimize Individual Therapy Response to Renin-Angiotensin-Aldosterone System Intervention.
Journal: Clinical journal of the American Society of Nephrology : CJASN
Published: January 12, 2017
Differential Effects of Dapagliflozin on Cardiovascular Risk Factors at Varying Degrees of Renal Function.
Journal: Clinical journal of the American Society of Nephrology : CJASN
Published: September 28, 2016
Variability in response to albuminuria-lowering drugs: true or random?
Journal: British journal of clinical pharmacology
Published: June 15, 2016
Showing 1-8 of 8
Last Updated: 09/26/2026